查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1382559

全球眼科用藥市場預測（至2030年）

Ophthalmic Topical Therapeutics Market Forecast till 2030
出版日期: | 出版商: Market Research Future | 英文 148 Pages | 訂單完成後即時交付

價格

在預測期（2023-2030年），全球眼科局部治療市場規模預計將以 7.25% 的複合年增長率大幅增長。

老年人口的增加和眼疾的傳播推動了市場的發展。 屈光不正、乾眼、青光眼、視覺過敏和老年黃斑部病變等眼部疾病在全球呈上升趨勢，推動了市場成長。

區域考慮

2022年北美市場佔最大份額。 關鍵變數是眼疾患者數量的增加、老年人口的增加以及該地區存在大量市場公司。

歐洲市場佔第二大份額。 原因是已開發國家人口老化、醫療服務全球化以及糖尿病和其他併發症的增加。

預計2023年至2030年亞太市場成長最快。 這是由於眼科疾病負擔的增加、消費者意識的提高以及尖端創新的廣泛採用。 每個組織都在為患者創造和傳播新的治療方案方面進行重要工作。

本報告提供了全球眼科局部治療市場的研究和分析，包括市場動態、區域和細分市場分析以及公司概況。

目錄

第 1 章執行摘要

第二章市場介紹

第三章研究方法

第 4 章市場動態

  • 摘要
  • 促進因素
    • 老年人口增加
    • 眼科疾病流行
  • 抑制因素
    • 對眼科疾病缺乏認識
  • 機會
    • 正在研發的外用藥物數量不斷增加

第五章市場因素分析

  • 價值鏈分析
    • 研究與開發
    • 製造業
    • 分銷/銷售
    • 售後監控
  • 波特五力分析模型
  • COVID-19 對眼科局部治療市場的影響
    • 對供應鏈的影響
    • 對生產的影響
    • 對市場進入者的影響

第 6 章全球眼科局部治療市場:依產品類型

  • 摘要
  • 人工淚液
  • 抗過敏
  • 抗生素眼藥水
  • 抗發炎
  • 抗青光眼
  • 其他

第七章全球眼科外用藥物市場:依疾病分類

  • 摘要
  • 乾眼症
  • 眼睛過敏
  • 青光眼
  • 眼部感染
  • 視網膜疾病
  • 葡萄膜炎
  • 其他

第 8 章全球眼科局部治療藥物市場:按劑型

  • 摘要
  • 眼藥水
  • 凝膠
  • 軟膏
  • 其他

第 9 章全球眼科局部治療藥物市場:依通路劃分

  • 摘要
  • 醫院藥房
  • 藥局
  • 網路藥局
  • 其他

第 10 章全球眼科局部治療市場:按地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 韓國
    • 亞太地區其他地區
  • 其他領域
    • 中東
    • 非洲
    • 拉丁美洲

第十一章競爭態勢

  • 摘要
  • 競爭基準測試
  • 全球眼科局部治療市場的主要成長策略
  • 全球眼科局部治療市場的主要公司（按開發數量）
  • 主要進展分析
  • 主要發展與成長策略
    • 產品核准及產品上市/管道藥物
    • 合作夥伴/隸屬關係
    • 業務擴展/合約
    • 併購
  • 主要企業銷售分析
    • 銷售/營業利潤
  • 主要企業研發分析

第十二章公司簡介

  • SANTEN PHARMACEUTICAL CO., LTD.
  • SUN PHARMACEUTICAL INDUSTRIES LTD
  • NOVARTIS AG
  • ABBVIE INC.
  • BAUSCH & LOMB INCORPORATED
  • AMNEAL PHARMACEUTICALS LLC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • ALCON
  • VIATRIS INC.

第13章附錄

Product Code: MRFR/HC/10564-HCR

Market Overview

The Ophthalmic Topical Therapeutics is estimated to register a significant CAGR of 7.25% during the forecast period (2023 - 2030).

This market is being driven by a few elements, remembering an ascent for geriatric populace and expanding pervasiveness of ophthalmic problems.

There is a rising commonness of ophthalmic problems like refractive blunders, dry eye, glaucoma, eye sensitivities, and age-related macular degeneration internationally which is driving the market development. As per the WHO in October 2021, somewhere around 2.2 billion individuals universally experience the ill effects of vision weakness. The main sources of vision hindrance are refractive blunders and waterfall, the two of which have topical ophthalmic restorative items accessible on the lookout. Essentially, glaucoma is a main source of irreversible visual impairment universally. As indicated by Public Glaucoma Exploration, north of 3 million Americans have glaucoma. As per the WHO in 2021, over 7.7 million individuals experience the ill effects of glaucoma worldwide. The most widely recognized treatment for glaucoma is remedy eye drops like beta-blockers, prostaglandins, Rho-kinase inhibitors, and others that can hold glaucoma back from deteriorating.

Market Segmentation

The Market fragments of Ophthalmic Topical Therapeutics, based on type, incorporates fake tears, against sensitivity, anti-toxin drops, mitigating, antiglaucoma, and others. The Market division, in view of disease type, incorporates dry eye, eye sensitivity, glaucoma, eye disease, retinal issues, uveitis, and others. In view of dose form, the worldwide ophthalmic topical therapeutics industry is divided into eye drops, gels, salves, and others.

The Market division of Ophthalmic Topical Therapeutics, in view of distribution channel, incorporates clinic drug stores, pharmacies, online drug stores, and others.

Regional Insights

The North America ophthalmic topical therapeutics market represented the biggest piece of the pie in 2022. Key variables credited to its rising commonness of eye sickness, rising geriatric populace, and the presence of an enormous number of market players in the district. Moreover, the rising commonness of ophthalmic illnesses is driving the market interest for ophthalmic topical therapeutics in North America. Factors like an expansion in the geriatric populace, progressions in innovative work in optometry, and the expansion in the utilization of ophthalmic medications in emergency clinic drug stores are supposed to expand the interest for ophthalmic topical therapeutics in the US.

Europe ophthalmic topical therapeutics market represented the second-biggest piece of the pie because of expanding geriatric populace in the created nations, globalization of medical services, and rising weight of diabetes and other comorbidities.

The Asia-Pacific ophthalmic topical therapeutics market is supposed to be the quickest developing from 2023 to 2030 because of the rising expanding weight of ophthalmic problems and rising buyer mindfulness, and the developing reception of cutting-edge innovations. Organizations are going into key drives to create and popularize new treatment choices for patients.

Major Players

Key Companies in the market of ophthalmic topical therapeutics includes Santen pharmaceutical co., Ltd. (Japan), Sun Pharmaceutical Industries Ltd (India), Novartis AG (Switzerland), AbbVie (US), Bausch & Lomb Incorporated (US), Amneal Pharmaceuticals., LLC (US), Teva Pharmaceutical Industries Ltd. (Israel), Alcon (Switzerland), Akorn Operating Company LLC (US), and Viatris Inc. (US).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 OVERVIEW

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE
  • 2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5 FORECASTING TECHNIQUES
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.6.1 BOTTOM-UP APPROACH
    • 3.6.2 TOP-DOWN APPROACH
  • 3.7 DATA TRIANGULATION
  • 3.8 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 RISE IN GERIATRIC POPULATION
    • 4.2.2 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS
  • 4.3 RESTRAINTS
    • 4.3.1 LACK OF AWARENESS REGARDING EYE DISORDERS
  • 4.4 OPPORTUNITIES
    • 4.4.1 GROWING NUMBER OF TOPICAL DRUGS IN THE PIPELINE

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION & SALES
    • 5.1.4 POST-SALES MONITORING
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 THREAT OF SUBSTITUTES
    • 5.2.4 BARGAINING POWER OF BUYERS
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19 ON THE OPHTHALMIC TOPICAL THERAPEUTICS MARKET
    • 5.3.1 IMPACT ON SUPPLY CHAIN
    • 5.3.2 IMPACT ON PRODUCTTION
    • 5.3.3 IMPACT ON MARKET PLAYERS

6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE

  • 6.1 OVERVIEW
  • 6.2 ARTIFICIAL TEARS
  • 6.3 ANTI-ALLERGY
  • 6.4 ANTIBIOTIC DROPS
  • 6.5 ANTI-INFLAMMATORY
  • 6.6 ANTIGLAUCOMA
  • 6.7 OTHERS

7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE

  • 7.1 OVERVIEW
  • 7.2 DRY EYE
  • 7.3 EYE ALLERGY
  • 7.4 GLAUCOMA
  • 7.5 EYE INFECTION
  • 7.6 RETINAL DISORDERS
  • 7.7 UVEITIS
  • 7.8 OTHERS

8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM

  • 8.1 OVERVIEW
  • 8.2 EYE DROPS
  • 8.3 GELS
  • 8.4 OINTMENTS
  • 8.5 OTHERS

9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 9.1 OVERVIEW
  • 9.2 HOSPITAL PHARMACIES
  • 9.3 DRUG STORES
  • 9.4 ONLINE PHARMACIES
  • 9.5 OTHERS

10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
    • 10.2.1 US
    • 10.2.2 CANADA
  • 10.3 EUROPE
    • 10.3.1 GERMANY
    • 10.3.2 UK
    • 10.3.3 FRANCE
    • 10.3.4 ITALY
    • 10.3.5 SPAIN
    • 10.3.6 REST OF EUROPE
  • 10.4 ASIA-PACIFIC
    • 10.4.1 JAPAN
    • 10.4.2 CHINA
    • 10.4.3 INDIA
    • 10.4.4 AUSTRALIA
    • 10.4.5 SOUTH KOREA
    • 10.4.6 REST OF ASIA-PACIFIC
  • 10.5 REST OF THE WORLD
    • 10.5.1 MIDDLE EAST
    • 10.5.2 AFRICA
    • 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 COMPETITIVE BENCHMARKING
  • 11.3 MAJOR GROWTH STRATEGY IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
  • 11.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
  • 11.5 KEY DEVELOPMENT ANALYSIS
  • 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 11.6.1 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS
    • 11.6.2 PARTNERSHIP/COLLABORATION
    • 11.6.3 BUSINESS EXPANSIONS/AGREEMENTS
    • 11.6.4 MERGERS & ACQUISITIONS
  • 11.7 MAJOR PLAYERS SALES ANALYSIS
    • 11.7.1 SALES & OPERATING INCOME
  • 11.8 MAJOR PLAYERS R&D ANALYSIS

12 COMPANY PROFILES

  • 12.1 SANTEN PHARMACEUTICAL CO., LTD.
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 FINANCIAL OVERVIEW
    • 12.1.3 PRODUCTS/SERVICES OFFERED
    • 12.1.4 KEY DEVELOPMENTS
    • 12.1.5 KEY STRATEGIES
  • 12.2 SUN PHARMACEUTICAL INDUSTRIES LTD
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 FINANCIAL OVERVIEW
    • 12.2.3 PRODUCTS/SERVICES OFFERED
    • 12.2.4 KEY DEVELOPMENTS
    • 12.2.5 KEY STRATEGIES
  • 12.3 NOVARTIS AG
    • 12.3.1 COMPANY OVERVIEWS
    • 12.3.2 FINANCIAL OVERVIEW
    • 12.3.3 PRODUCTS/SERVICES OFFERED
    • 12.3.4 KEY DEVELOPMENTS
    • 12.3.5 SWOT ANALYSIS
    • 12.3.6 KEY STRATEGIES
  • 12.4 ABBVIE INC.
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 FINANCIAL OVERVIEW
    • 12.4.3 PRODUCTS OFFERED
    • 12.4.4 KEY DEVELOPMENTS
    • 12.4.5 SWOT ANALYSIS
    • 12.4.6 KEY STRATEGIES
  • 12.5 BAUSCH & LOMB INCORPORATED
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 FINANCIAL OVERVIEW
    • 12.5.3 PRODUCTS OFFERED
    • 12.5.4 KEY DEVELOPMENTS
    • 12.5.5 SWOT ANALYSIS
    • 12.5.6 KEY STRATEGIES
  • 12.6 AMNEAL PHARMACEUTICALS LLC.
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 FINANCIAL OVERVIEW
    • 12.6.3 PRODUCTS/SERVICES OFFERED
    • 12.6.4 KEY DEVELOPMENTS
    • 12.6.5 KEY STRATEGIES
  • 12.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 12.7.1 COMPANY OVERVIEW
    • 12.7.2 FINANCIAL ANALYSIS
    • 12.7.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 12.7.4 KEY DEVELOPMENTS
    • 12.7.5 SWOT ANALYSIS
    • 12.7.6 KEY STRATEGIES
  • 12.8 ALCON
    • 12.8.1 COMPANY OVERVIEW
    • 12.8.2 FINANCIAL OVERVIEW
    • 12.8.3 PRODUCTS/SERVICES/SOLUTIONS 0FFERED
    • 12.8.4 KEY DEVELOPMENTS
    • 12.8.5 SWOT ANALYSIS
    • 12.8.6 KEY STRATEGIES
  • 12.9 AKORN OPERATING COMPANY LLC
    • 12.9.1 COMPANY OVERVIEW
    • 12.9.2 FINANCIAL OVERVIEW
    • 12.9.3 PRODUCTS/SERVICES/SOLUTIONS OFFERED
    • 12.9.4 KEY DEVELOPMENTS
    • 12.9.5 KEY STRATEGIES
  • 12.10 VIATRIS INC.
    • 12.10.1 COMPANY OVERVIEW
    • 12.10.2 FINANCIAL OVERVIEW
    • 12.10.3 PRODUCTS/SERVICES OFFERED
    • 12.10.4 KEY DEVELOPMENTS
    • 12.10.5 KEY STRATEGIES

13 APPENDIX

  • 13.1 REFERENCES
  • 13.2 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • TABLE 3 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 4 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ARTIFICIAL TEARS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 5 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTI-ALLERGY, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 6 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTIBIOTIC DROPS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 7 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTI-INFLAMMATORY, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 8 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ANTIGLAUCOMA, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 11 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR DRY EYE, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 12 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE ALLERGY, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 13 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR GLAUCOMA, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 14 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE INFECTION, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 15 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR RETINAL DISORDERS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 16 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR UVEITIS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 17 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 18 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 19 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR EYE DROPS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 20 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR GELS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 21 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OINTMENTS, BY REGION, 22019-2030 (USD BILLION)
  • TABLE 22 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 23 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 24 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 25 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR DRUG STORES, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 26 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 27 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, FOR OTHERS, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 28 GLOBAL: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION, 2019-2030 (USD BILLION)
  • TABLE 29 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
  • TABLE 30 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 31 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 32 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 33 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 34 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 35 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 36 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 37 US: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 38 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 39 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 40 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 41 CANADA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 42 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
  • TABLE 43 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 44 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 45 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 46 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 47 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 48 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 49 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 50 GERMANY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 51 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 52 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 53 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 54 UK: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 55 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 56 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 57 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 58 FRANCE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 59 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 60 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 61 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 62 ITALY: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 63 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 64 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 65 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 66 SPAIN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 67 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 68 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 69 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 70 REST OF EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 71 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY, 2019-2030 (USD BILLION)
  • TABLE 72 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2019-2030 (USD BILLION)
  • TABLE 73 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 74 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 75 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 76 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
  • TABLE 77 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
  • TABLE 78 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
  • TABLE 79 JAPAN: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 80 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
  • TABLE 81 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
  • TABLE 82 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
  • TABLE 83 CHINA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 84 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
  • TABLE 85 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
  • TABLE 86 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
  • TABLE 87 INDIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030 (USD BILLION)
  • TABLE 88 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
  • TABLE 89 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 90 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
  • TABLE 91 AUSTRALIA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
  • TABLE 92 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030 (USD BILLION)
  • TABLE 93 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030 (USD BILLION)
  • TABLE 94 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030 (USD BILLION)
  • TABLE 95 SOUTH KOREA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
  • TABLE 96 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DEVICE TYPE, 2019-2030(USD BILLION)
  • TABLE 97 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2019-2030(USD BILLION)
  • TABLE 98 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2019-2030(USD BILLION)
  • TABLE 99 REST OF ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2019-2030(USD BILLION)
  • TABLE 100 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY COUNTRY 2019-2030(USD BILLION)
  • TABLE 101 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030(USD BILLION)
  • TABLE 102 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030(USD BILLION)
  • TABLE 103 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
  • TABLE 104 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
  • TABLE 105 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
  • TABLE 106 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030 (USD BILLION)
  • TABLE 107 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
  • TABLE 108 MIDDLE EAST: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
  • TABLE 109 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
  • TABLE 110 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030(USD BILLION)
  • TABLE 111 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030(USD BILLION)
  • TABLE 112 AFRICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030 (USD BILLION)
  • TABLE 113 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE 2019-2030 (USD BILLION)
  • TABLE 114 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE 2019-2030 (USD BILLION)
  • TABLE 115 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM 2019-2030 (USD BILLION)
  • TABLE 116 LATIN AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 2019-2030(USD BILLION)
  • TABLE 117 MAJOR MANUFACTURERS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
  • TABLE 118 MOST ACTIVE PLAYER IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
  • TABLE 119 PRODUCT APPROVALS AND PRODUCT LAUNCHES/PIPELINE DRUGS
  • TABLE 120 PARTNERSHIP/COLLABORATION
  • TABLE 121 BUSINESS EXPANSIONS/ AGREEMENTS
  • TABLE 122 MERGERS & ACQUISITIONS
  • TABLE 123 SANTEN PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED
  • TABLE 124 SANTEN PHARMACEUTICAL CO., LTD.: KEY DEVELOPMENTS
  • TABLE 125 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED
  • TABLE 126 GENENTECH, INC.: KEY DEVELOPMENTS
  • TABLE 127 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 128 NOVARTIS AG.: KEY DEVELOPMENTS
  • TABLE 129 ABBVIE INC.: PRODUCTS OFFERED
  • TABLE 130 ABBVIE INC.: KEY DEVELOPMENTS
  • TABLE 131 BAUSCH & LOMB INCORPORATED: PRODUCTS OFFERED
  • TABLE 132 BAUSCH & LOMB INCORPORATED: KEY DEVELOPMENTS
  • TABLE 133 AMNEAL PHARMACEUTICALS LLC.: PRODUCTS OFFERED
  • TABLE 134 AMNEAL PHARMACEUTICALS., LLC.: KEY DEVELOPMENTS
  • TABLE 135 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 136 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS
  • TABLE 137 ALCON: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 138 ALCON: KEY DEVELOPMENTS
  • TABLE 139 AKORN OPERATING COMPANY LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 140 VIATRIS INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 141 VIATRIS INC.: KEY DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 4 MARKET DYNAMICS: OPHTHALMIC TOPICAL THERAPEUTICS MARKET
  • FIGURE 5 DRIVERS: IMPACT ANALYSIS
  • FIGURE 6 RESTRAINT: IMPACT ANALYSIS
  • FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
  • FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
  • FIGURE 9 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2022 & 2030 (USD BILLION)
  • FIGURE 10 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY PRODUCT TYPE, 2022
  • FIGURE 11 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISEASE TYPE, 2022 & 2030 (USD BILLION)
  • FIGURE 12 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY DISEASE TYPE, 2022
  • FIGURE 13 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DOSAGE FORM, 2022 & 2030 (USD BILLION)
  • FIGURE 14 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY DOSAGE FORM, 2022
  • FIGURE 15 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2030 (USD BILLION)
  • FIGURE 16 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2021
  • FIGURE 17 GLOBAL: OPHTHALMIC TOPICAL THERAPEUTICS MARKET, BY REGION 2022 & 2030 (USD BILLION)
  • FIGURE 18 GLOBAL: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY REGION 2022
  • FIGURE 19 NORTH AMERICA: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
  • FIGURE 20 EUROPE: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
  • FIGURE 21 ASIA-PACIFIC: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
  • FIGURE 22 REST OF THE WORLD: OPHTHALMIC TOPICAL THERAPEUTICS MARKET SHARE (%), BY COUNTRY, 2022
  • FIGURE 23 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 24 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET
  • FIGURE 25 GLOBAL OPHTHALMIC TOPICAL THERAPEUTICS MARKET: COMPETITIVE LANDSCAPE
  • FIGURE 26 MAJOR PLAYERS SALES & OPERATING INCOME, 2022 (USD BILLION)
  • FIGURE 27 MAJOR PLAYERS R&D EXPENDITURE, 2022 (USD BILLION)
  • FIGURE 28 SANTEN PHARMACEUTICAL CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 30 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 NOVARTIS AG.: SWOT ANALYSIS
  • FIGURE 32 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 33 ABBVIE INC.: SWOT ANALYSIS
  • FIGURE 34 BAUSCH & LOMB INCORPORATED: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 35 BAUSCH & LOMB INCORPORATED: SWOT ANALYSIS
  • FIGURE 36 AMNEAL PHARMACEUTICALS LLC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 37 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 38 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
  • FIGURE 39 ALCON: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 40 ALCON: SWOT ANALYSIS
  • FIGURE 41 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT